Navigation Links
Pharsight Expands Global Consulting Services Teams
Date:10/15/2007

New Hires and Expanded Internship Program Strengthen Strategic Consulting

Services, Reporting and Analysis Staff in Europe and Canada

MOUNTAIN VIEW, Calif., Oct. 15 /PRNewswire-FirstCall/ -- Pharsight Corporation (OTC Bulletin Board: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced the expansion of its scientific consulting services practices with three new hires. Pharsight has also expanded its internship program, which is designed to foster knowledge of modeling and simulation amongst graduate students in a variety of scientific disciplines.

Pharsight has hired Lars Lindbom, Ph.D., as a senior associate scientist in its Strategic Consulting Services (SCS) group, based in Europe. Dr. Lindbom joins Pharsight from Uppsala University's department of Pharmaceutical Biosciences in Sweden, where he held a postdoctoral research fellowship sponsored by Pfizer. He also served as a bioinformatics software systems developer within the discovery research organization at AstraZeneca. Dr. Lindbom has broad experience with population pharmacokinetic and pharmacodynamic (PK/PD) modeling and pharmacometric method development, with an emphasis in computer-intensive statistical methods.

Dr. Lindbom holds a Ph.D. from Uppsala University's department of Pharmaceutical Biosciences, within the National Network in Drug Development, Swedish Foundation for Strategic Research. Dr. Lindbom has authored or co- authored several original research articles in the field of pharmacostatistical modeling and has given invited presentations on Perl- speaks-NONMEM (PsN), a collection of computer programs aiding in the development of non-linear mixed effects models using NONMEM, to which he was a developer and remains an active contributor.

Pharsight's recently launched Reporting and Analysis Services (RAS) business unit has added a PK scientist in response to increased global demand for the group's PK/PD analysis and reporting services. The RAS team has also added a Quality Assurance Inspector to support delivery of high quality, regulatory-compliant clinical study analyses and reports for new drug approval. Since its launch in May 2007, the RAS unit has more than tripled its staff and has plans to expand its facilities in Montreal, Canada. In addition, the RAS unit has accepted into its internship program a student working towards a Ph.D. in Pharmaceutical Sciences at the University of Montreal.

"The addition of new expert staff in both the SCS and RAS business units will further enhance our ability to address the full spectrum of client needs in modeling and simulation," said Shawn O'Connor, president, chief executive officer and chairman of Pharsight. "Lars brings to SCS a wealth of expertise in the area of PK/PD modeling and advanced statistical methods. The addition of yet another talented, highly experienced scientist in the SCS group will help us meet the growing demand for applying model-based drug development approaches to support our client's decision-making processes."

"In addition to the expansion of the SCS team, we have continued to grow our RAS group's capabilities by bringing on new talent," continued Mr. O'Connor. "Requirements for regulatory-compliant analysis and reporting of PK/PD data to support new drug submissions has driven new customer demand for our RAS offering. We are pleased to extend Pharsight's internship program to cover our entire consulting services practice, which provides talented Ph.D. students with opportunities to work on projects and gain in-depth modeling and simulation expertise. We look forward to contributions from our newest colleagues that will further enhance the services that we provide to our clients."

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com.

Registered Trademarks and Trademarks

Pharsight is a registered trademark of Pharsight Corporation. All other brand or product names mentioned in this documentation are trademarks or registered trademarks of their respective companies or organizations.


'/>"/>
SOURCE Pharsight Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. The Cleveland Clinic Expands Its Services across the World via the Net
2. Ranbaxy Expands By Acquiring A Generic Company In Belgium
3. Insulin and Growth Hormone, Expands Life Span?
4. Health Insurance Company Expands Product Range
5. Bird Flu Outbreak Expands in Vietnam
6. Skin Cancer Research To Go Global
7. Dementia - a global problem
8. Obesity a global problem
9. Suggestions to reduce global heart disease burden
10. Drop in global deaths from measles
11. First global SARS meet opens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... February 05, 2016 , ... Steven Tonkinson, 36, of Coconut Grove, ... year since it started in 2003. This year, he ran all 26.2 miles with ... and NBA team the Miami Heat. , This Sunday, while many are watching the ...
(Date:2/5/2016)... Minneapolis, MN (PRWEB) , ... February 05, 2016 , ... ... p.m. at the Day Block Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will ... , Larry Schneiderman, owner of Schneiderman’s Furniture, lives with Parkinson’s disease and is the ...
(Date:2/5/2016)... Toronto, Ontario (PRWEB) , ... February 05, 2016 , ... ... the Scarborough General Hospital Burn Unit, plastic and cosmetic surgeon Dr. Wayne Carman transitioned ... the Scarborough Hospital. He successfully completed his first three-year term as chief and began ...
(Date:2/5/2016)... ... February 05, 2016 , ... Regular gym users know the routine: each ... longer to access the treadmills. It’s a predictable trend. After the excesses of November ... get in shape by joining gyms, starting new walking or running routines, or signing ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Dr. Justin Scott ... their 2nd Annual No Cost Dental Day to individuals in need. The event is ... of this No Cost Dental Day is to provide dental care to community members ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... 5, 2016  Syneron Medical Ltd. (NASDAQ: ... announced today that William Griffing , Chief ... scheduled to participate in the Leerink Partners 5 ... 11, 2016 in New York City ... to meet with the Mr. Griffing and will ...
(Date:2/5/2016)... DUBLIN , Feb. 5, 2016 /PRNewswire/ ... announced the addition of the "Global ... financials" company profile to their offering. ... announced the addition of the "Global ... financials" company profile to their offering. ...
(Date:2/5/2016)... 2016  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... underwritten secondary offering of 11,027,558 shares of its common ... of Blackstone and Goldman Sachs.  The shares are being ... $96.45 per share. The selling stockholders will receive all ... nor any of its directors, officers or other stockholders ...
Breaking Medicine Technology: